NCT03023553View on ClinicalTrials.gov

The Human Mucosal Immune Responses to Influenza Virus (SLVP026)

PHASE4CompletedINTERVENTIONAL
Enrollment

13

Participants

Timeline

Start Date

December 31, 2012

Primary Completion Date

February 28, 2013

Study Completion Date

February 28, 2013

Conditions
Influenza
Interventions
BIOLOGICAL

Fluzone®

Influenza Virus Vaccine Suspension for Intramuscular Injection

BIOLOGICAL

FluMist®

Influenza Virus Vaccine Live, Intranasal Spray

All Listed Sponsors
collaborator

National Institute of Allergy and Infectious Diseases (NIAID)

NIH

lead

Stanford University

OTHER

NCT03023553 - The Human Mucosal Immune Responses to Influenza Virus (SLVP026) | Biotech Hunter | Biotech Hunter